110 - Kodiac Sciences FALLS on Negative Wet AMD Readout! Buying Opportunity or Falling Knife??
Вставка
- Опубліковано 15 гру 2024
- Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their recent P3 wet AMD data readout failed to show non-inferiority to Q8W dosed Eylea, a major upset for the company. However, KOD has a number of other upcoming P3 trial readouts that will be massive movers for the stock. In this episode, I go over the P3 data and talk about whether or not this is a buying opportunity.
I also talk about Karyopharm and their recent regulatory update about the SIENDO data.
Thanks to InfoPathways for being a sponsor of the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929.
Help out the show (or join the discord) by becoming a patron at: / breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech
Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
dude….that was amazing analyst of KOD, so very insightful!! So summer of 23 brings major catalyst. KOD still on your watchlist?
Top notch….thanks again!!
I got a big position here myself. Do we go back to 40-50?
Good show. I apparently got in at about the time you got in, waiting to sit it out. Obviously the stock is way oversold at this point.
Thanks Carl! Agreed
Does Julian Baker still own KOD ? It may have bottomed around $4.25 and I anticipate a rally into the July '23 Phase 3 Announcement which is pending.
Great call I think it's still got a long ways to run here.
He owns more now than ever before
Would love to know your latest thoughts after the positive topline RVO results!
Great news! It's obviously a much smaller market than wet AMD, but KOD is not out of the race. Looks like in line with their guidance after the wet AMD failure, that their trial design hurt them because the protocol prevented additional injections. I sold out of my position because it doesn't look like there is much on the calendar until 2023. I might re-enter but need some time to look at the other indications.
@@breakingbiotech thanks so much. Appreciate your response and sharing your own strategy on this. I retained my holdings only because my avg is around $27, and I'm selling aggressive calls to minimize loss and stay in the game (by reselling same strike puts). I'm disappointed the good news didn't drive price action to a 1B mkt cap.
Also, Perlroth (CEO) mentioned in an interview to Jeffries that they did not have an opportunity to change the dosage frequency for Beacon (recent RVO study), whereas they did for the future trials, hence that bodes quite well, too.
Great show! I know you’ve covered TGTX a couple of times in the past, but wondering your thoughts on them now, given the drastic price drop due to the pending ODAC meeting next month. I still think there’s a good chance of approval for the CLL indication, and have even more confidence in the pending MS decision. With a ~$800M enterprise value, the risk reward looks really good to me at this point, and I’ve been accumulating this past week.
I have to take another look. FDA clearly does not like PI3K inhibitors and I think investors are pricing in that risk now. Seems like the selling is overdone, but it's a tough biotech market right now.
Pleaww give an update on Kodiak